Immunitas Therapeutics is a Waltham, MA-based therapeutics company that uses a single cell genomics platform to identify and validate immune targets in parallel with antibody discovery and engineering. The company is advancing multiple programs derived from its platform, including lead asset IMT-009, a first-in-class CD161 inhibitor modulating NK and T cells, and IMT-073, a dual-target NK and T cell modulator. Immunitas intends to use the new funds to advance IMT-009 into the clinic for both solid tumors and hematological malignancies. The company is led by CEO Jeffrey Goldberg and recently appointed Amanda Wagner as Chief Business Officer. Since its 2019 founding, Immunitas has raised a total of $97 million in venture funding from a syndicate of strategic and life-sciences investors. Immunitas employs a single cell genomics-based platform to dissect the tumor microenvironment and identify novel immune targets from human samples. The company has generated fully humanized monoclonal antibodies with single-agent activity in preclinical oncology models. Immunitas plans to advance its lead programs into human efficacy studies and clinical trials, driven by specific clinical biomarkers derived from its platform. The company was founded by Longwood Fund and is presented from Boston. Its scientific founders and leaders include pioneers in tumor immunobiology who contributed to the platform and target discovery. Immunitas intends to use its approach to accelerate translation of human biology into candidate therapeutics and patient-selection biomarkers.

Total raised

$97M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2021